World Cell and Gene Therapy Summit on November 10-12, 2026 in Incheon, Republic of Korea

South Korea is rapidly advancing its cell and gene therapy (CGT) ecosystem, with key milestones such as Curocell's Rimqarto becoming the first MFDS-approved cell therapy, and continued innovation from companies like Vaxcellbio and Rznomics advancing next-generation modalities. More recently, breakthroughs in in vivo CAR therapies, enhanced LNP and AAV delivery platforms, and advanced manufacturing have accelerated development timelines in the clinic.

The inaugural World Cell and Gene Therapy Summit South Korea unites international and local industry experts to share insights into better understanding of cellular microenvironments and gene editing tools. From T-Cells, NK cells, macrophages, and stem cells, the agenda will explore how different cell types are being harnessed to combat oncology, autoimmune diseases and beyond.

As part of the World Advanced Therapeutics Summit by Hanson Wade, this event offers a platform to connect with leaders across cell, gene and RNA therapies working to establish South Korea as a global hub for advanced biopharma innovation.

URLs:

Tickets: https://go.evvnt.com/3703445-2?pid=10008

Brochure: https://go.evvnt.com/3703445-3?pid=10008

Time: 8:30 AM - 3:15 PM

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 2199.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 1999.00,

Drug Developer Pricing - Conference Only: USD 1799.00,

Academic Pricing - Conference + 2 Workshops: USD 1899.00,

Academic Pricing - Conference + 1 Workshop: USD 1749.00,

Academic Pricing - Conference Only: USD 1599.00,

Service Provider Pricing - Conference + 2 Workshops: USD 5149.00,

Service Provider Pricing - Conference + 1 Workshop: USD 4499.00,

Service Provider Pricing - Conference Only: USD 3849.00

Speakers: Gena Lee Meyers, Business Development Lead, Curocell, Peggy Sotiropoulou, Chief Scientific Officer, T-Knife Therapeutics, Tae-Ho Hwang, Chief Technology Officer, Bionoxx, Xian Zeng, Chief Executive Officer, Byterna Therapeutics, Tina Albertson, Chief Medical Officer, Caribou Biosciences, Jihwan Song, Professor, Founder and Chief Technology Officer, CHA University and iPS Bio, Jeonghoon Han, Chief Executive Officer, Cunnovative, DongHyuk Jeon, Director of Production Center, Curocell, Jiyeon Son, Team Leader, GC Biopharma, Aida Rouzmehr, Material Science Product Lead, Genentech, Ting-Wan Lin, Director of Business Development and Project Manager, GenomeFrontier Therapeutics, Bryan Choi, Professor, INHA University, Mihue Jang, Principal Research Scientist, Korea Institute of Science and Technology, Heesoon Chang, Chief Executive Officer, KW-Bio, Minsung Choy, Director of Regulatory Affairs, Cell Therapy, Legend Biotech, Juhi Verma, Manager, Micro CRISPR, Seungryul Han, Head of R and D (Director), Rznomics, Gi-Hoon Nam, Chief Executive Officer, Shiftbio, Cheng-Yi Jerry Kuo, Vice General Manager, UWELL BioPharma, Je-Jung Lee, Chief Executive Officer, Vaxcell Bio